Apellis Pharmaceuticals-JPM-20240108 .pdf

《Apellis Pharmaceuticals-JPM-20240108 .pdf》由会员分享，可在线阅读，更多相关《Apellis Pharmaceuticals-JPM-20240108 .pdf（30页珍藏版）》请在三个皮匠报告上搜索。

1、42ndAnnual J.P.Morgan Healthcare Conference 2024Cedric Francois,M.D.,Ph.D.Chief Executive OfficerJanuary 8,20242Forward-looking statementsStatements in this presentation about future expectations,plans and prospects,as well as any other statements regarding matters that are not historical facts,may

2、constitute“forward-looking statements”within the meaning of The Private Securities Litigation Reform Act of 1995.These statements include,but are not limited to,statements regarding preliminary financial information for the fourth quarter and full year ended December 31,2023 and the appeal and re-ex

3、amination of the MAA if CHMP issues a negative opinion for intravitreal pegcetacoplan and the safety profile of intravitreal pegcetacoplan.The words“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“intend,”“may,”“plan,”“potential,”“predict,”“project,”“should,”“target,”“will,”“would”and

4、similar expressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,including adjustme

5、nts to Apellis preliminary revenue figures resulting from,among other things,the completion of financial closing and review procedures for the quarter and year ended December 31,2023;whether the benefit/risk profile of SYFOVRE following the reported events of retinal vasculitis will impact our comme

6、rcialization efforts;whether SYFOVRE will receive approval from foreign regulatory agencies for GA when expected or at all,including the impact on the likelihood and timing of such approvals;and other factors discussed in the“Risk Factors”section of Apellis Annual Report on Form 10-K with the Securi